Mobile

A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and m...

Update Il y a 4 ans
Reference: EUCTR2007-003723-21

A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the safety and tolerability of vildagliptin (50 mg qd) vs. placebo in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment.

Inclusion criteria

  • Diabetes Type 2 together with moderate or severe renal insufficiency

Links